FTC rules Impax received illegal payments to block pain reliever generic
01-04-2019
FTC approves Amneal’s $1.45bn acquisition of Impax
11-07-2018
Amneal and Impax merge to become ‘fifth largest’ generics company
19-10-2017
designer491 / iStockphoto.com
The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FTC, Federal Trade Commission, generics, Amneal Pharmaceuticals, Impax Laboratories, mergers and acquisitions, M&S, anticompetitive
